Many treatments are double-edged swords, and it cannot be denied that the emergence of CAR-T therapy has given many patients who had no other options a choice and even the possibility of long-term survival. The rapidly growing market size has also led more companies to enter the CAR-T race.
Faced with this controversy, many companies have expressed confidence in the safety of their CAR-T therapy. Industry insiders stated, "To date, CAR-T cell therapy has treated 35,000 patients worldwide, and all the information disclosed by the FDA actually pertains to 19 cases out of 35,000 patients. Whether this is a coincidence or a certainty is unknown. Additionally, even without CAR-T cell therapy, multiple myeloma patients may also develop T-cell malignancies."
